Key Highlights
- Shares trading up 20.82% pre-market, adding $2.85 to reach $16.56
- Q2 2026 Revenue of $28.5 million beat the $12.7 million estimate by 124.79%
- Adjusted EPS of $0.15 beat the expected loss of $0.27 by 155.56%
- YARTEMLEA gross revenue nearly tripled sequentially to $32.2 million, with net product revenue pushing near $28.5 million
- Reduced 2029 convertible note principal and ongoing interest by 43% through buybacks
- Medicare will provide additional hospital reimbursement for YARTEMLEA starting in October
Blowout Earnings Surprise Drives Pre-Market Surge
Omeros (NASDAQ:OMER) shares are surging in pre-market trading Thursday, up 20.82% to $16.56, after the company posted a Blowout second-quarter 2026 earnings surprise driven by its newly launched rare-disease drug YARTEMLEA. Revenue reached $28.5 million, beating the $12.7 million estimate by 124.79%, while adjusted EPS of $0.15 beat the expected loss of $0.27 by 155.56%. Gross revenue from the drug nearly tripled sequentially to $32.2 million, pushing net product revenue near $28.5 million versus consensus estimates near $12.7 million.
Omeros Corporation is a Seattle-based biopharmaceutical company founded in 1994 that discovers, develops, and commercializes small-molecule and protein therapeutics for large-market and orphan indications targeting complement-mediated diseases, inflammation, immuno-oncology, and disorders of the central nervous system and addiction. Its lead asset, narsoplimab, marketed as YARTEMLEA, targets the lectin pathway of complement and has completed pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy, with a Biologics license application pending before the FDA, while also being studied in Phase III trials for IgA nephropathy and atypical hemolytic uremic syndrome.
Balance Sheet Strengthened, Reimbursement Momentum Building
Investors are also responding to balance-sheet improvements, including a 43% reduction in 2029 convertible note principal and ongoing buybacks, alongside recent news that Medicare will provide additional hospital reimbursement for YARTEMLEA starting in October, supporting adoption expectations even as the company still awaits a re-examination of a negative EU regulatory opinion on the drug in TA-TMA.
Adult utilization now represents approximately 75% of sales, approaching an 85/15 adult and pediatric transplant split, with 73 unique ordering accounts, up 143% since the first quarter, across 175 U.S. transplant centers, and coverage and reimbursement approval at 55 to 60% of tracked centers. The company generated positive Operating Cash Flow of $4.1 million in the quarter and ended with $132 million in cash and investments.
Conclusion
Omeros' 20.82% pre-market surge reflects a blowout earnings surprise driven by rapid early adoption of YARTEMLEA, with gross sales nearly tripling sequentially and both revenue and earnings beating estimates by triple-digit percentages. With Medicare reimbursement expanding in October and the company targeting company-wide cash flow positivity by mid-2027, the stock's next moves will likely hinge on continued adoption momentum across the expanding transplant center network.






Please wait processing your request...